Table 1.
Baseline characteristics of the trial participants
| Trial arms | ||||
|---|---|---|---|---|
| BIAsp 30 (n = 82) | NPH/Reg (n = 82) | P value | ||
| Age (years) | 58.50 ± 14.04 | 57.24 ± 10.88 | 0.072 | |
| Sex (male/female) | 33/49 | 29/53 | 0.343 | |
| Diabetes Duration (years) | 13.60 ± 3.12 | 15.62 ± 4.86 | 0.194 | |
| HbA1c (%) | 9.55 ± 1.03 | 9.97 ± 1.52 | 0.576 | |
| TG (mg/dl) | 183.19 ± 11.33 | 191.22 ± 55.11 | 0.153 | |
| Total Chol (mg/dl) | 184.41 ± 21.31 | 176.33 ± 22.30 | 0.254 | |
| LDL (mg/dl) | 103.72 ± 19.70 | 110.39 ± 14.56 | 0.348 | |
| HDL (mg/dl) | 45.34 ± 11.05 | 48.55 ± 15.12 | 0.176 | |
| BMI (kg/m2) | 29.37 ± 6.78 | 31.78 ± 7.52 | 0.211 | |
| Prior OGLD treatment (n, %) | Metformin | 25 (30.48) | 27 (32.92) | 0.972 |
| Sulfonylurea | 9 (10.97) | 9 (10.97) | ||
| Metformin + Sulfonylurea | 40 (48.78) | 39 (47.56) | ||
| Thiazolidinedione | 4 (4.87) | 5 (6.09) | ||
Abbreviations: BIAsp biphasic insulin aspart 30, NPH/Reg NPH plus regular human insulin, HbA1c hemoglobin A1c, TG triglyceride, Chol cholesterol, LDL low density lipoprotein, HDL high density lipoprotein, BMI body mass index, OGLD oral glucose lowering drugs